Freeze-dried jaboticaba peel powder improves insulin sensitivity in high-fat-fed mice

Nathalia R. V. Dragano1*, Anne y Castro Marques1, Dennys E. C. Cintra2, Carina Solon3, Joseane Morari3, Alice V. Leite-Legatti1, Lício A. Velloso3 and Mário R. Marostica-Júnior1

1Department of Food and Nutrition, Faculty of Food Engineering, University of Campinas (UNICAMP), Monteiro Lobato 80, 13083-862 Campinas, São Paulo, Brazil
2College of Applied Sciences, University of Campinas, Pedro Zaccaria Street, 1300, 13484-350 Limeira, São Paulo, Brazil
3Laboratory of Cell Signaling, Faculty of Medical Sciences, University of Campinas, Carlos Chagas Street, 420, 13084-970 Campinas, São Paulo, Brazil

(Submitted 30 May 2012 – Final revision received 16 October 2012 – Accepted 16 October 2012 – First published online 18 February 2013)

Abstract

The peel of the native Brazilian fruit jaboticaba is rich in anthocyanins, which are known for their anti-obesity effects in animal models. The aim of the present study was to evaluate the effects of freeze-dried jaboticaba peel powder (FDJPP) on a number of metabolic parameters in a model of diet-induced obesity. Mice (n 8 per group) were initially fed on a high-fat diet (HFD, 35% w/w) for 4 weeks and then switched to a HFD supplemented with FDJPP (1, 2 or 4% w/w) for an additional 6 weeks. Energy intake, weight loss, glucose tolerance, insulin resistance and lipid profile were determined, and the results were evaluated using ANOVA and Tukey’s tests. The FDJPP exerted no protective effect on HFD-induced weight gain, hyperleptinaemia and glucose intolerance. However, the supplementation was effective to reduce insulin resistance, as evidenced in the insulin tolerance test, and subsequently confirmed by improved signal transduction through the insulin receptor/insulin receptor substrate-1/Akt/forkhead box protein pathway and by the attenuation of HFD-induced inflammation in the liver, verified by lower expressions of IL-1β and IL-6 and decreased phosphorylated IκB-α protein levels in all jaboticaba-treated mice. These results suggest that FDJPP may exert a protective role against obesity-associated insulin resistance.

Key words: Jaboticaba; Obesity; Insulin resistance

Obesity has reached epidemic proportions in the world, with substantial adverse consequences for human health1). A number of life-threatening diseases, such as type 2 diabetes mellitus, dyslipidaemia, CVD, hypertension and certain types of cancer, are associated with this condition1,2. Nutritional factors are known to play an important role in the development of a number of diseases. The recent changes in human lifestyle, with the introduction of high-fat/simple carbohydrate-rich diets, are amongst the most important factors leading to the increased prevalence of obesity. Conversely, epidemiological data suggest that increased consumption of fruits and vegetables are positively associated with the prevention of metabolic disorders, including obesity3,4. The ability of some vegetable-derived nutrients to reduce the risk of chronic diseases has been associated, at least in part, with the occurrence of bioactive non-nutrient compounds that are known to exert a wide range of biological activities5,6.

Anthocyanins, which belong to the flavonoid class, are an example of such bioactive compounds. They constitute the largest and probably the most important group of watersoluble natural pigments responsible for the vivid blue, purple and red colour of many vegetables and fruits7. Many reports have shown that anthocyanin exhibits an array of pharmacological properties, such as anti-inflammatory and anticarcinogenic activities, as well as preventive effects on CVD and degenerative disease. The majority of research has focused on the antioxidant properties of these dietary polyphenols8. Furthermore, it has been shown that phenolic compounds can exert modulatory action in cells by interacting with a wide range of molecular targets of intracellular signalling machinery to elicit their beneficial effects9.

Abbreviations: C, control group; FDJPP, freeze-dried jaboticaba peel powder; FoxO, forkhead transcription factor box; HF, high-fat group; HFD, high-fat diet; HFJ1%, high-fat diet plus 1% (w/w) freeze-dried jaboticaba peel powder group; HFJ2%, high-fat diet plus 2% (w/w) freeze-dried jaboticaba peel powder group; HFJ4%, high-fat diet plus 4% (w/w) freeze-dried jaboticaba peel powder group; iGTT, intraperitoneal glucose tolerance test; IκB-α, inhibitor of NF-κB; IRS1, insulin receptor substrate 1; ITT, insulin tolerance test.

* Corresponding author: N. R. V. Dragano, fax +55 19 3521 8950, email nathdragano@hotmail.com
Recent findings have suggested that the consumption of anthocyanins may reduce obesity and some of its associated disorders, at least in animal models\(^{10–12}\). However, additional in vivo studies have reported that whole powdered berries in high-fat diets, compared with purified anthocyanins, were not quite effective in preventing obesity. Actually, they showed the potential to increase obesity\(^{13,14}\).

**Jaboticaba** (*Myrciaria jaboticaba*) is an indigenous Brazilian fruit found in the largest part of the country, particularly in the Southeast. The mature fruit is round and has a thick, dark purple, astringent skin that covers a sweet, white, gelatinous flesh. The fruit is widely used in Brazil, where it is mostly consumed fresh and, to a smaller extent, as jams and liqueurs. A recent study published by our research group showed that cyanidin-3-O-glucoside and delphinidin-3-O-glucoside are the major constituents found in the freeze-dried jaboticaba peel. The total content of anthocyanins analysed by HPLC was 2599·3 mg/100 g of freeze-dried jaboticaba peel. The total content of the major anthocyanin (75·6 % of total anthocyanins) (Table 1)(15).

Several flavonoids, phenolic acids and terpenes are also present in jaboticaba\(^{16–18}\). These flavonoids may reduce obesity and some of its associated disorders, at least in animal models\(^{10–12}\). However, additional in vivo studies have reported that whole powdered berries in high-fat diets, compared with purified anthocyanins, were not quite effective in preventing obesity. Actually, they showed the potential to increase obesity\(^{13,14}\).

In addition, we have previously found that the consumption of 1, 2 and 4 % freeze-dried jaboticaba peel was able to reduce the hyperinsulinaemia and increased serum HDL-cholesterol in Sprague–Dawley rats fed a high-fat diet (HFD), but did not promote a reduction of the weight gain in the animals. However, the mechanisms involved remain to be elucidated\(^{19}\).

The present study was designed to investigate the effect and mechanisms possibly involved in using freeze-dried jaboticaba peel powder (FDJPP) on glucose tolerance and insulin resistance in high-fat-fed mice.

**Experimental methods**

**Freeze-dried jaboticaba peel powder**

Jaboticaba (*M. jaboticaba* Vell berg) was obtained directly from the producer (Aguiá, São Paulo State, Brazil) during the main harvest season in September 2008. The fruit was manually washed with fresh water and the peel was separated and frozen at −20°C. The frozen peel was lyophilised and grounded into a fine powder by an electrical mill. The FDJPP was kept in airtight containers and stored at −80°C. The analysis of macronutrients, total protein, moisture and ash was performed according to methods described by the Association of Official Analytical Chemists\(^{20}\). The total lipids were determined according to the Bligh & Dyer\(^{21}\) method and the determination of soluble and insoluble fibres was performed according to Asp et al.\(^{22}\). The concentration of carbohydrate was calculated as the difference between 100 and the percentage total of the content of protein, fat, moisture and ash. The identification and quantification of anthocyanins in FDJPP were determined using MS and HPLC, as described previously by our group\(^{15}\).

**Experimental animals and diets**

Male Swiss inbred strain mice (21 d of age), originally imported from the Jackson Laboratory and currently bred at the University of Campinas Breeding Center (University of Campinas, SP, Brazil), were weaned at 21 d of age and individually housed in polycarbonate cages in a temperature-controlled room with a 12-hr light/dark cycle. All experimental procedures were approved by the University’s animal care committee and were in accordance with the guidelines of the Society for Experimental Biology and Medicine and the Brazilian College of Animal Experimentation. The animals were randomly assigned to one of five dietary groups: control (C), high-fat (HF), high-fat plus 1 % freeze-dried jaboticaba peel powder (HFJ1 %), high-fat plus 2 % freeze-dried jaboticaba peel powder (HFJ2 %) and high-fat plus 4 % freeze-dried jaboticaba peel powder (HFJ4 %). The diets were isocaloric and isonitrogenous, containing different levels of jaboticaba peel powder. The macronutrient composition of the diets was adjusted to provide isocaloric levels of carbohydrates, protein and lipids, as shown in Table 1.

**Table 1. Composition of experimental diets**

<table>
<thead>
<tr>
<th>Ingredients (g/kg diet)</th>
<th>C</th>
<th>HF</th>
<th>HFJ1 %</th>
<th>HFJ2 %</th>
<th>HFJ4 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein†</td>
<td>151.5</td>
<td>151.5</td>
<td>151.5</td>
<td>151.5</td>
<td>151.5</td>
</tr>
<tr>
<td>Maize starch</td>
<td>428.0</td>
<td>251.3</td>
<td>253.3</td>
<td>255.3</td>
<td>259.3</td>
</tr>
<tr>
<td>Maltodextrin</td>
<td>142.2</td>
<td>83.4</td>
<td>83.4</td>
<td>83.4</td>
<td>83.4</td>
</tr>
<tr>
<td>Sucrose</td>
<td>107.8</td>
<td>63.3</td>
<td>63.3</td>
<td>63.3</td>
<td>63.3</td>
</tr>
<tr>
<td>Cellulose</td>
<td>50</td>
<td>50</td>
<td>48</td>
<td>46</td>
<td>42</td>
</tr>
<tr>
<td>Soyabean oil</td>
<td>70</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Lard</td>
<td>0</td>
<td>310</td>
<td>310</td>
<td>310</td>
<td>310</td>
</tr>
<tr>
<td>Mineral mixture</td>
<td>35</td>
<td>35</td>
<td>35</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td>Vitamin mixture</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>L-Cys</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Tert-butylhydroquinone</td>
<td>0.014</td>
<td>0.014</td>
<td>0.014</td>
<td>0.014</td>
<td>0.014</td>
</tr>
<tr>
<td>Jaboticaba peel powder</td>
<td>0</td>
<td>0</td>
<td>10</td>
<td>20</td>
<td>40</td>
</tr>
<tr>
<td>Total</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
</tr>
<tr>
<td>Anthocyanins (mg/kg diet)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyanidin-3-O-glucoside</td>
<td>0</td>
<td>196.4</td>
<td>392.8</td>
<td>785.6</td>
<td></td>
</tr>
<tr>
<td>Delphinidin-3-O-glucoside</td>
<td>0</td>
<td>0</td>
<td>63.5</td>
<td>127</td>
<td>254</td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>0</td>
<td>259.9</td>
<td>519.8</td>
<td>1039.6</td>
</tr>
<tr>
<td>Energy density (kJ/g diet)</td>
<td>16·3</td>
<td>23·0</td>
<td>23·0</td>
<td>23·0</td>
<td>23·0</td>
</tr>
</tbody>
</table>

*C, control group; HF, high-fat group; HFJ1 %, high-fat diet plus 1 % (w/w) freeze-dried jaboticaba peel powder group; HFJ2 %, high-fat diet plus 2 % (w/w) freeze-dried jaboticaba peel powder group; HFJ4 %, high-fat diet plus 4 % (w/w) freeze-dried jaboticaba peel powder group;† Amount was calculated based on protein content equal to 79·2 %.

*Diets were prepared according to the formulation of the American Institute of Nutrition for AIN-93G\(^{23}\) with modified protein content to 12 % according to Goena et al.\(^{24}\).
Brazil), were used in the study. The investigation was approved by the Ethics Committee for Animals (Permission: 2020-1/2010; University of Campinas, SP, Brazil) and followed the University guidelines for the use of animals in experimental studies. The animals were maintained at 21 ± 3°C, on an artificial 12 h light–12 h dark cycle and housed in individual cages. They were then randomly divided into five groups, with eight mice per treatment (following an initial acclimatisation period of 7 d). All groups were balanced for initial body weight. The treatments were control group (C): mice were fed on a normal diet, based on the AIN-93G(23); control high-fat group (HF): mice were fed on a HFD, containing 4% (w/w) soyabean oil and 31% (w/w) lard; HFD plus 1% (w/w) FDJPP (HFJ1%); HFD plus 2% (w/w) FDJPP (HFJ2%) and HFD plus 4% (w/w) FDJPP (HFJ4%). Mice (HFJ1%, HFJ2% and HFJ4%) were initially fed on a HFD for 4 weeks and then switched to a HFD containing FDJPP for an additional 6 weeks. The diets were replaced at intervals of 3 d to prevent fat and anthocyanin oxidation. Because the FDJPP has significant amounts of fibre (20% insoluble fibre and 5% soluble fibre(19), the content of dietary fibre present in supplemented diets was adjusted to eliminate the influence of this important component over the present findings. The concentration of freeze-dried powder in the diets and anthocyanins content were determined according to preliminary studies conducted by our research group(15,19). The composition of the diets, energy densities and anthocyanin content are presented in Table 1. Body weight and food intake were measured weekly.

**Intraperitoneal glucose tolerance test and insulin tolerance test**

An intraperitoneal glucose tolerance test (IGTT) and insulin tolerance test (ITT) were performed on food-deprived (6 h) non-anesthetised mice after 9 and 10 weeks of treatment, respectively. Blood glucose levels were measured with an Optium™ mini (Abbott Diabetes Care) handheld glucometer using appropriate test strips. For the IGTT, a solution of 20% glucose (2.0 g/kg body weight) was administered into the peritoneal cavity. Blood samples were collected from the tail vein at 30, 60, 90 and 120 min following the determination of glucose concentrations. The AUC of glucose was calculated. For the ITT, glucose blood levels were sampled at 5, 10, 15, 20, 25 and 30 min following intraperitoneal injection of human insulin (0.75 U 4.5 mmol/kg; NovoRapid, Novo Nordisk). The constant rate for glucose disappearance during the ITT (KITT) was calculated using the formula 0.693/t1/2. The glucose t1/2 was calculated from the slope of the least-square analysis of the plasma glucose concentrations during the linear decay phase(24).

**Serum, liver and adipose tissue samples**

After 10 weeks of diet consumption, the fasting (12 h) mice were anaesthetised (sodium thiopental 50 mg/kg body weight) and blood samples were taken from the inferior vena cava. Serum was obtained by centrifugation (1500g for 15 min at 4°C) and immediately frozen at −80°C until use. The liver and epididymal adipose tissue were removed and processed according to the subsequent analysis.

**Serum sample analysis**

The serum TAG, total cholesterol and HDL-cholesterol were assayed enzymatically using commercial kits (Laborlab). Serum leptin was measured by ELISA using a commercial kit (Mouse leptin ELISA kit; Millipore).

**Protein immunoblotting analysis**

For evaluation of cytokine expression, protein activity and insulin signal transduction in the liver and adipose tissue, the abdominal cavities of anaesthetised mice were opened, the portal vein exposed and 100 µl (10−6 mol/l) of insulin or saline solution were injected. Fragments (3 x 3 x 3 x 3 mm) of liver (at 30 µl) and epididymal adipose tissue (at 2 min) were excised after the infusion of insulin and immediately homogenised in extraction buffer (1% Triton X-100, 100 mM-Tris (pH 7.4), containing 100 mM-sodium pyrophosphate, 100 mM-sodium fluoride, 10 mM-EDTA, 10 mM-sodium vanadate, 2 mM-phenylmethylsulfonylfluoride and 0.1 mg/ml aprotonin) at 4°C with a Polytron® System PT 10-35 (Brinkmann Instruments) operated at maximum speed for 15 s. The extracts were centrifuged at 9000 g at 4°C for 40 min to remove insoluble material, and the protein concentration of the supernatant was determined by the Biuret method(25). The immunoblotting was performed on tissue extracts as previously described by Thirone et al.(26), with minor modifications. The proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted with antibodies against phospho-insulin receptor β (IR) (#2907; Cell Signaling), phosphor-insulin receptor substrate (IRS)-1 (#9272; Cell Signaling) and phospho-Akt (sc-7985-R; Santa Cruz Biotechnology) and IL-6 (sc-1252; Santa Cruz Biotechnology). Specific bands were labelled by chemiluminescence and visualisation was performed by exposure of the membranes to RX films. Band intensity was quantified by digital densitometry (ScionCorp) and normalised with β-actin.

**RNA extraction and quantitative real-time PCR**

Total RNA was extracted using a commercially available acid-phenol reagent, Trizol (Invitrogen). RNA integrity was confirmed by non-denaturing agarose gel electrophoresis. First-strand complementary DNA was synthesised using SuperScript III RT and random hexamere primers, as described in the manufacturer’s protocol (Invitrogen). Quantitative PCR was run to determine the expression of IL-1β (Rn00580432_m1; Applied Biosystems) and IL-6 (Mm00475338_m1; Applied Biosystems) in the liver of treated mice using the primer supplied by Applied Biosystems. The reference gene was glyceraldehyde-3-phosphate dehydrogenase (g352339E; Applied Biosystems). Real-time PCR analysis of gene expression was carried out in an ABI Prism 7500 sequence detection system.
system (Applied Biosystems). Each PCR contained 25 ng of reverse-transcribed RNA and was run according to the manufacturer's recommendations using the TaqMan PCR master mix. Real-time data were analysed using the Sequence Detector System 1.7 (Applied Biosystems). Results were expressed as relative transcript amounts.²⁷

Data analysis and statistics

Analyses were performed using Statsoft Statistica 7 software. Initially, all data were subjected to the Shapiro–Wilk's and Levene's test to verify the data distribution and variance homogeneity, respectively. When necessary, the data were log-transformed to fulfill parametric requirements. Parametric data were evaluated using one-way ANOVA and non-parametric data using Kruskal–Wallis followed by post hoc testing for significance (P<0.05, by Tukey–Kramer or Dunnett's test, respectively). Results were expressed as means with their standard errors for parametric data and medians and ranges for non-parametric data.

Results

Body weight, food and energy intake

As expected, after 10 weeks, body mass gain was significantly higher in mice fed on the HFD compared with the low-fat control diet (C). This difference was evidenced after the second experimental week (Fig. 1). The addition of FDJPP to the HFD did not protect the animals against HFD-induced body mass gain, while the cumulative body mass gain in mice fed on HFJ2% was significantly greater, 31.62 (SEM 0.9) and 23.25 (SEM 1.4) g, respectively. In all the remaining groups receiving FDJPP, body mass increased when compared with the HFD, but this was not significant (Fig. 1).

The overall food intake (g/mouse per d) did not differ among control and high-fat groups throughout the experiment (data not shown). It is important to notice that control mice consumed the same amount of food (weight) as mice on the HFD. However, energy intake was higher on the HF diets, approximately 96.3 kJ/d. Mice from the control group consumed 68.5 kJ/d. In mice fed on the HFD plus 2 and 4% FDJPP, the energy intake was significantly greater than the HF group (Fig. 2). Thus, a higher energy intake was associated with a greater cumulative weight gain throughout the experiment in these treatments.

Serum lipids and leptin concentrations

Fasting serum TAG, total cholesterol and HDL-cholesterol were not altered by level of fat or FDJPP in the diet (data not shown). Serum leptin levels increased with body weight (control group v. HFD groups); nevertheless, this trend did not reach statistical significance, probably due to the small number of animals used in this analysis (n 4) (Fig. 3).

Glucose intolerance and insulin resistance

The AUC values for plasma glucose levels during the iGTT were significantly increased in all HFD groups compared with the control group (Fig. 4(a)). These results demonstrated that glucose intolerance in control HFD-fed mice was not ameliorated by FDJPP treatments.

The contribution of insulin sensitivity to glucose intolerance was investigated by determining the clearance of plasma glucose as a function of time after insulin injection (ITT). This measure of whole-body insulin sensitivity can be expressed by constant rate for glucose disappearance (KITT); larger values indicate greater tissue insulin sensitivity. Notably, mice fed on the HFD plus FDJPP showed a significant increase in KITT values compared with the mice fed the HFD, and the KITT did not differ from the control group (Fig. 4(b)). These data suggest that FDJPP may prevent HFD-induced insulin resistance in mice.

Insulin signalling pathway

In order to evaluate possible mechanisms responsible for the enhancement of insulin sensitivity of FDJPP, we examined insulin signalling through the IR/IRS1/Akt/FoxO pathway in the liver and adipose tissue of mice. Impairment in all insulin signalling cascade steps was detected in the HF control group. As shown in Fig. 5, significant improvement in insulin signal
transduction was observed through the increased insulin-mediated tyrosine phosphorylation of IR and IRS-1, serine phosphorylation of Akt in the liver and adipose tissue and threonine phosphorylation of FoxO in the liver of mice treated with FDJPP when compared with the HF control mice.

Inflammation

Because previous studies have shown that chronic activation of intracellular proinflammatory pathways within the insulin target cells might contribute to the obesity-related insulin resistance, we evaluated whether FDJPP could modulate HFD-induced inflammation. Remarkably, the mRNA levels of the cytokines IL-6 and IL-1β from the liver of the HFJ groups were significantly reduced, except for the mRNA levels of IL-1β found in the HFJ2% group (Fig. 6(a) and (b)). This effect was accompanied by a significant decrease in the phosphorylated IκB-α protein levels in the liver of all mice treated with FDJPP compared with the HF mice (Fig. 7). These improvements were comparable with those of the lean control mice.

Discussion

Recently, much attention has been focused on natural bioactive phytochemicals present in food that may provide desirable health benefits. The potential of bioactive components to treat or prevent obesity is under intense exploration, and this represents a strategy for developing safe anti-obesity approaches. Emerging reports have provided evidence of the importance of anthocyanins as dietary antioxidants for the prevention of oxidative damage. Lately, several studies have gradually focused on their beneficial effects in preventing obesity and diabetes.

The present study demonstrates that supplementation of a HFD with jaboticaba peel does not produce significant protection against body weight gain and, in fact, tends to increase cumulative weight gain, accompanied by no difference in food and energy intake. We also observed no changes in serum lipid content and leptin levels in mice fed on the FDJPP-enriched diets. Similarly, recent studies have also reported that whole freeze-dried powders of Concord grapes, blueberry and black raspberry were ineffective in preventing obesity and, in some cases, they could increase body weight gain and adiposity relative to a HFD. However, purified anthocyanins from various sources, including purple maize, Cornelian cherry, black soybean coats, blueberries and strawberries, have shown positive responses in HFD-induced obesity, such as decrease in body weight gain and improvement in lipid profile, hyperleptinaemia and hyperglycaemia to levels similar to control mice. Reasons for the different response between whole foods and purified extracts of anthocyanins are still not fully elucidated. The possible therapeutic effects of anthocyanins are certainly dependent on sufficient bioavailability and not on the exact amount of anthocyanins consumed. Other components present in the whole food matrix may possibly reduce the rate of absorption and bioactivity of anthocyanins, counteracting in some way to prevent any protective effect against obesity.

The FDJPP supplementation did not attenuate HFD-induced hyperglycaemia either, which was reflected in a larger incremental iGTT AUC of the plasma glucose. The pathogenesis of glucose intolerance is complex and is mainly a function of the interplay between insulin sensitivity and endocrine pancreatic function. In the present study, we demonstrated that mice fed on HFJ diets for 6 weeks were protected from hyperglycaemia to levels similar to control mice.
Fig. 5. Representative immunoblots (IB) of insulin signalling proteins in (a) adipose tissue and (b) liver of control (C); high-fat (HF); high-fat diet plus 1 % (w/w) freeze-dried jaboticaba peel powder (HFJ1 %); high-fat diet plus 2 % (w/w) freeze-dried jaboticaba peel powder (HFJ2 %) and high-fat diet plus 4 % (w/w) freeze-dried jaboticaba peel powder (HFJ4 %) groups before (−) or after (+) insulin stimulation. * Values were significantly different from the HF group (P < 0.05).
† Values were significantly different from the C group (P < 0.001). IR, insulin receptor; IRS1, insulin receptor substrate 1.
phosphorylated IkB-α protein levels in liver of all treated mice in a dose-independent manner. Similarly, DeFuria et al. demonstrated that blueberry supplementation can protect against whole-body insulin resistance by inhibiting the early inflammatory events in adipose tissue, induced by HFD in mice.

In addition, systemic oxidative stress, a persistent imbalance between the production of highly reactive molecular species and antioxidant defenses, correlates with fat accumulation in human subjects and mice. The hypothesis that oxidative stress is a causative factor in the development of insulin resistance has been supported by several studies that showed that reversal of the imbalance between reactive oxygen species and antioxidants improves insulin resistance.

Reactive oxygen species can activate a number of cellular stress-sensitive pathways that cause cellular damage and are linked to insulin resistance and chronic inflammation. The
chronic and/or increased production of these reactive molecules or a reduced capacity for their elimination can lead to the activation of multiple stress-sensitive serine/threonine kinase signalling cascades such as IkB-β, resulting in reduced insulin action\(^{40}\).

Our previous study demonstrated that the addition of 1 and 2% of FDJPP to a control diet improved the antioxidant capacity of rat's plasma (1.7 times by the Trdox equivalent antioxidant capacity method and 1.3 times by the oxygen radical absorbance capacity assay). Taking all this information into account, FDJPP seems to exert a protective role against HFD-induced insulin resistance in mice in different ways. This might be due to the ability of FDJPP anthocyanins and/or other related bioactive antioxidants to exert their effects as free radical scavengers, preventing to some degree the increase in reactive oxygen species levels. They could also modulate cellular stress signalling processes during inflammation, acting as signalling agents by inhibiting the NF-κB signal pathway, thus, preventing the development of insulin resistance in treated mice, in accordance with the results shown here.

It is worth highlighting that FDJPP is a complex byproduct and its phytochemical composition has not been fully elucidated. Thus, the beneficial health-promoting effects observed here and in previous studies may not be solely attributed to the high total anthocyanin content. Although in lower concentrations, studies have revealed that jabuticaba is also a dietary source of other phenolic compounds like quercetin and ellagic acid\(^{37,49}\). Results, both in cell culture and in animal models, have shown that quercetin has anti-obesity potential, improving glucose homeostasis, and it is able to modulate inflammation through a variety of mechanisms\(^{40}\). Similarly, recent studies have found that pomegranate flowers and fruit extracts, which also contain abundant anthocyanins and hydrolysable tannins, have strong antioxidant, anti-inflammatory properties, appetite-suppressant activity and they have improved insulin sensitivity in diabetic animals\(^{41–43}\). Therefore, these bioactive compounds may also have contributed to the effects observed in the present study. Despite the fact that FDJPP is a remarkable source of dietary fibre, in the present work, the influence of this component on the results was unlikely to be due to the adjustments made in the supplemented diets.

Here, we demonstrated that impaired glucose tolerance observed in mice fed with the HFD diets is not due to insulin resistance. It is well-known that dietary antioxidants, including anthocyanins, protect pancreatic β-cells from glucose-induced oxidative stress. One possibility is that the FDJPP treatment for 6 weeks is not efficient to reverse the β-cell dysfunction, as observed after exposure to high glucose levels, elevated NEFA levels or both during the first 4 weeks on the HFD. It is important to emphasise the fact that previous studies have shown that the β-cells are an additional target for the oxidative stress. These cells are particularly sensitive to reactive oxygen species because they are low in antioxidant enzymes such as catalase, glutathione peroxidase and superoxide dismutase\(^{38,44}\).

Conclusion

A HFD containing FDJPP, rich in anthocyanins, was ineffective in altering the effects of the HFD on body weight and glucose intolerance; however, the supplementation was efficient in correcting diet-induced insulin resistance, which may be associated, at least in part, to the reduced inflammation in the liver of the treated mice. These findings raise issues that require further investigation.

Acknowledgements

The present work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). N. R. V. D., A. C. M., D. E. C. C., L. A. V. and M. R. M.-J. designed the research; A. V. L.-L. provided and analysed the FDJPP, N. R. V. D., A. C. M., D. E. C. C., C. S. and J. M. conducted experimental work; N. R. V. D., A. C. M., D. E. C. C., C. S. and L. A. V. analysed the data; N. R. V. D. wrote the paper; N. R. V. D. and M. R. M.-J. had the primary responsibility for the final content of the paper. The authors declare that they have no conflict of interest.

References


